Evaluation of imatinib mesylate (Gleevec) on KAI1/CD82 gene expression in breast cancer MCF-7 cells using quantitative real-time PCR
10.1016/j.apjtb.2015.10.006
- Author:
Seyed Ataollah Sadat SHANDIZ
1
;
Amir MIRZAIE
1
;
Hamidreza JOUZAGHKAR
1
;
Marjan KHOSRAVANI
2
;
Sepideh MOHAMMADI
3
;
Hassan NOORBAZARGAN
4
;
Davoud Nouri INANLOU
5
;
Mojgan Dalirsaber JALALI
6
;
Fahimeh BAGHBANI-ARANI
7
;
Behta KESHAVARZ-PAKSERESHT
7
Author Information
1. Young Researchers and Elite Club, East Tehran Branch, Islamic Azad University
2. Department of Microbiology, Shiraz Azad University
3. Department of Microbiology, Islamic Azad University, Pharmaceutical Sciences Branch
4. Department of Biotechnology, Shahid Beheshti University of Medical Sciences
5. R and D Department, Research and Production Complex, Pasteur Institute of Iran
6. Department of Microbiology, Faculty of Basic Science, Young Researcher Club, Lahijan Branch, Islamic Azad University
7. Department of Genetics and Biotechnology, School of Biological Science, Varamin-Pishva Branch, Islamic Azad University
- Publication Type:Journal Article
- Keywords:
Breast cancer;
Imatinib mesylate;
KAI1/CD82;
Metastasis;
Real-time PCR
- From:Asian Pacific Journal of Tropical Biomedicine
2016;6(2):159-163
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To evaluate the effect of imatinib mesylate on cell viability, anti cancer effect through modulation of KAI1/CD82 gene expression in breast cancer MCF-7 cell line. Methods: The effects of imatinib mesylate on cell viability in MCF-7 cell line were assessed using MTT assay and IC
